Evidence map›Paper›PMID 35923829›Full record

ArticleFrontiers in neurology2022

Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2.

Stojan Peric, Jelena Zlatar, Luka Nikolic, Vukan Ivanovic, Jovan Pesovic, Ivana Petrovic Djordjevic, Svetlana Sreckovic, Dusanka Savic-Pavicevic, Giovanni Meola, Vidosava Rakocevic-Stojanovic

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Stojan PericNeurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
Jelena ZlatarFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Luka NikolicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Vukan IvanovicNeurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
Jovan PesovicCenter for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.
Ivana Petrovic DjordjevicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Svetlana SreckovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Dusanka Savic-PavicevicCenter for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.
Giovanni MeolaDepartment of Neurorehabilitation Sciences, Casa Di Cura del Policlinico, Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Vidosava Rakocevic-StojanovicNeurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
University of Belgrade · RSCentar za Promociju Nauke · RSUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). Aim: The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. Patients and Methods: A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. Results: Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, Conclusion: AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2.

Indexed as

antineutrophil cytoplasmic antibodiesantinuclear antibodiesautoimmune diseasesHashimoto autoimmune thyroiditismyotonic dystrophy type 2 (DM2)

Identifiers

PMID35923829
PMCPMC9341519
OpenAlexW4285801480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.